Product Design for High-Performance Detergent Applications
Optimize formulations for detergent components, ensure specific functions and protect valuable ingredients.
Optimize formulations for detergent components, ensure specific functions and protect valuable ingredients.
We are delighted to announce a significant achievement for Glatt: the successful manufacturing of bioprocessing suites for insulin production for a client in Egypt. With the successful Factory Acceptance Test (FAT), this project marks our first venture in the bioprocessing sector outside of Asia, demonstrating our ability to meet diverse market demands while maintaining the highest standards of quality, innovation, and regulatory compliance.
Experience two exciting days with us at the PharmaCongress with interesting presentations on current topics that move the pharmaceutical world. A special highlight is the exciting presentation by Anton Kopitzsch, Glatt Team Lead Automation, and Andreas Bail, Bayer PCT Lead, on April 8 at 13:30: “Design & Implementation of a new highly automated modular OSD production plant at Bayer Leverkusen (Case Study)”.
Together with Rieckermann and joint partners we successfully hosted a seminar from December 3 to 5 at their Shanghai Technology Showcase Center focusing on “Quality by Design: Continuous Manufacturing Processes, In-process and Quality Control Technologies” to share latest technologies and experiences.
A Golden Batch is the perfect production run, where all key factors like temperature, pressure, and flow are aligned to create a high-quality product.
Innovative solutions and added value – Glatt at Achema 2024
Saxon State Minister of the Interior Armin Schuster and members of the Saxon State Parliament Martin Modschiedler and Ingo Flemming visit Glatt Systemtechnik GmbH Dresden
The new GCC coater impresses with more flexibility and improved containment
Sometime sales are closed with a small addition and a handshake.
The rapid transition from the benchtop to commercial production is crucial for a successful market launch, return on investment and to fully capitalise on the patent timeline.